ARTL CIK: 1621221

Artelo Biosciences, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
24.6
FY22:
18.3
FY23:
11.0
FY24:
2.56
FY25:
0.70
(positive)
Change from FY21 to FY25
millions USD
FY21:
3.64
FY22:
2.10
FY23:
2.06
FY24:
2.14
FY25:
2.11
Total assets
Change from FY21 to FY25
millions USD
FY21:
28.3
FY22:
20.4
FY23:
13.0
FY24:
4.70
FY25:
2.80

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
1.03
FY22:
1.00
FY23:
1.29
FY24:
1.77
FY25:
4.04
(negative)
Change from FY21 to FY25
millions USD
FY21:
0.06
FY22:
0.02
FY23:
0
FY24:
0.07
FY25:
0.03
(positive)
Change from FY21 to FY25
millions USD
FY21:
27.2
FY22:
19.4
FY23:
11.8
FY24:
2.86
FY25:
−1.27
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
28.3
FY22:
20.4
FY23:
13.0
FY24:
4.70
FY25:
2.80

All amounts in millions USD Data sources:SEC EDGARTwelve Data